Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
Agomelatine (AGM) is one of the latest atypical antidepressants, prescribed exclusively for the treatment of depression in adults. AGM belongs to the pharmaceutical class of melatonin agonist and selective serotonin antagonist (“MASS”), as it acts both as a selective agonist of melatonin receptors M...
Main Authors: | Rosa Savino, Anna Nunzia Polito, Gabriella Marsala, Antonio Ventriglio, Melanie Di Salvatore, Maria Ida De Stefano, Anna Valenzano, Luigi Marinaccio, Antonello Bellomo, Giuseppe Cibelli, Marcellino Monda, Vincenzo Monda, Antonietta Messina, Rita Polito, Marco Carotenuto, Giovanni Messina |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/13/5/734 |
Similar Items
-
Editorial: Multilingualism and neurodevelopmental disorders
by: Ai Leen Choo, et al.
Published: (2023-08-01) -
Microglial Dyshomeostasis: A Common Substrate in Neurodevelopmental and Neurodegenerative Diseases
by: Vada Andree Furlan, et al.
Published: (2024-05-01) -
A systematic review on the role of mitochondrial dysfunction/disorders in neurodevelopmental disorders and psychiatric/behavioral disorders
by: Daniela V. Pinto Payares, et al.
Published: (2024-06-01) -
Ketogenic Diet and Sport Performance
by: Fiorenzo Moscatelli, et al.
Published: (2020-02-01) -
Analyzing the Potential Biological Determinants of Autism Spectrum Disorder: From Neuroinflammation to the Kynurenine Pathway
by: Rosa Savino, et al.
Published: (2020-09-01)